ReShape Lifesciences (NSDQ:RSLS) said yesterday that its prez & CEO Dan Gladney will resign from his positions with the company, effective March 31. Gladney will remain with the company as board chair, San Clemente, Calif.-based ReShape Lifesciences said. The company’s board of directors said they will immediately begin to look for a replacement, according to an […]
vasculardynamics
Vascular Dynamics launches pivotal trial for MobiusHD hypertension device
Vascular Dynamics said yesterday that it launched a pivotal trial of its MobiusHD device to treat high blood pressure ahead of a bid for a nod from the FDA. The MobiusHD device is designed to help regulate blood pressure by reshaping the the carotid artery to stimulate baroreceptors and increase the body’s natural response to lower blood […]
Vascular Dynamics taps ex-Ellipse Tech CEO Roschak as chief exec | Personnel Moves December 15, 2017
Vascular Dynamics said early this month it tapped former NuVasive Inc. (NSDQ:NUVA) exec and Ellipse Technologies CEO Ed Roschak as its new president and chief executive. Prior to joining Mountain View, Calif.-based Vascular Dynamics, Roschak served as prez and CEO of Ellipse Technologies, which he saw through a $410 million acquisition by NuVasive. He then took up […]
Vascular Dynamics touts 6-month interim data from MobiusHD trial
Vascular Dynamics today released interim results from the 1st-in-human trial of its MobiusHD implant designed for treating resistant hypertension, touting a significant reduction in ambulatory systolic blood pressure at 6-months. The MobiusHD device is designed to help regulate blood pressure using electrodes implanted in the carotid artery to stimulate baroreceptors and increase the body’s natural […]
Vascular Dynamics touts significant BP reductions in interim MobiusHD trial results
Vascular Dynamics yesterday released interim results from the 1st-in-human trial of its MobiusHD implant designed for treating resistant hypertension, touting significant reductions in ambulatory systolic blood pressure. Results were released at the European Society of Cardiology’s annual meeting in Barcelona. The MobiusHD device is designed to help regulate blood pressure using electrodes implanted in the carotid […]
FDA approves pivotal study of Vascular Dynamics MobiusHD high blood pressure device
Vascular Dynamics said today that the FDA approved an investigational device exemption for a clinical trial of its MobiusHD device for treating resistant hypertension. MobiusHD is designed to help regulate blood pressure using electrodes implanted in the carotid artery to stimulate baroreceptors there. Mountain View, Calif.–based Vascular Dynamics said the 300-patient Calm 2 study is designed […]
Vascular Dynamics raises $10m for MobiusHD
Vascular Dynamics said this week that it closed a private placement worth $10.4 million that it plans to use on the clinical program for its MobiusHD device for treating drug-resistant hypertension. The MobiusHD implant is designed to reshape the carotid sinus to amplify the signals for baroreceptors lining the blood vessel. Implanted percutaneously, it’s designed to stimulate vasodilation. […]
NuVasive co-founder McKinley is Vascular Dynamics new COO | Personnel Moves June 9, 2016
NuVasive co-founder McKinley is Vascular Dynamics new COO Vascular Dynamics said it tapped NuVasive Inc. (NSDQ:NUVA) co-founder and former CEO James McKinley as its new chief operating officer. McKinley has held leadership positions at Advent Medical, Endosphere, Farallon Medical and Nellix, as well as NuVasive. “It is a tremendous opportunity to add Jim to our management team. […]
Vascular Dynamics wins CE Mark for MobiusHD hypertension device
Vascular Dynamics said today it won CE Mark approval for its MobiusHD minimally invasive hypertension treatment device. The MobiusHD is a passive implant delivered percutaneously designed to amplify signaling measured by the baroreceptors in the wall of the carotid sinus. The device reduces blood pressure due to the increase in baroreceptor signaling. “Receiving CE Mark approval for […]
VIVA 2015 Roundup: Medtronic touts Valiant stent graft, PAD stent-treatment data
Medtronic (NYSE:MDT) this week presented data from 2 studies of its stent systems and announced a new study of its In.Pact Admiral drug-coated balloon. The announcements were made at the VIVA physicians annual conference in Las Vegas, Nev. The Fridley, Minn.-based medical giant presented data from a 2-year clinical trial of its Valiant Captivia thoracic stent graft […]
Vascular Dynamics secures $17m Series B round
Vascular Dynamics said it secured $16.85 million in Series B financing to fund clinical trials for its device to treat drug-resistant hypertension.
